Mersana therapeutics, inc. (MRSN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Collaboration revenue

11

42

844

202

41,035

1,188

2,151

4,191

3,064

-

6,267

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

3,727

4,290

3,262

6,215

Operating expenses:
Research and development

12,219

12,430

13,701

13,766

15,143

19,816

15,180

12,663

12,256

14,555

11,412

10,627

10,106

7,555

8,171

General and administrative

4,936

4,212

4,436

4,192

4,443

4,152

4,380

4,231

3,571

3,057

2,905

2,204

2,296

1,598

1,826

Total operating expenses

17,155

16,642

18,137

17,958

19,586

23,968

19,560

16,894

15,827

17,612

14,317

12,831

12,402

9,153

9,997

Other income (expense):
Interest income

306

441

608

725

452

-

340

349

-

-

-

-

-

-

-

Interest expense

88

87

107

40

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

349

-

-

360

-

318

158

51

54

16

Total other income (expense), net

218

354

501

685

452

349

340

349

360

383

318

158

51

54

16

Net loss

-

-

-

-

-

-

-

-

-

-

-7,732

-8,946

-8,061

-

-

Net income (loss)

-16,926

-16,246

-16,792

-17,071

21,901

-22,431

-17,069

-12,354

-12,403

-

-

-

-

-5,837

-3,766

Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities

-29

-3

17

11

8

34

48

72

-13

-

-6

-9

-

-

-

Comprehensive income (loss)

-16,955

-16,249

-16,775

-17,060

21,909

-22,397

-17,021

-12,282

-12,416

-14,102

-7,738

-8,955

-8,061

-5,837

-3,766

Net loss attributable to common stockholders - basic

-16,926

-16,246

-16,792

-17,071

21,901

-22,431

-17,069

-12,354

-12,403

-13,968

-7,732

-8,946

-8,061

-

-

Net loss attributable to common stockholders - diluted

-16,926

-16,246

-16,792

-17,071

21,901

-22,431

-17,069

-12,354

-12,403

-

-7,732

-

-

-

-

Net loss per share attributable to common stockholders — basic and diluted (in dollars per share)

-

-

-0.35

-

-

-0.97

-0.74

-

-

9.48

-0.35

-6.33

-6.02

-4.56

-

Net loss per share attributable to common stockholders  basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3.00

Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic and diluted

-

-

47,833

-

-

23,184

23,152

-

-

23,098

22,242

1,412

1,338

1,279

1,254

Net income (loss) per share attributable to common stockholders — basic (in dollars per share)

-0.35

-

-

-0.36

0.72

-

-

-0.54

-0.54

-

-

-

-

-

-

Net income (loss) per share attributable to common stockholders — diluted (in dollars per share)

-0.35

-

-

-0.36

0.70

-

-

-0.54

-0.54

-

-

-

-

-

-

Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders — basic

47,988

-

-

47,708

30,299

-

-

22,966

22,816

-

-

-

-

-

-

Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders — diluted

47,988

-

-

47,708

31,461

-

-

22,966

22,816

-

-

-

-

-

-